Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson's disease and major depression

Journal of Neurology

Volumn 257, Issue 4, 2010, Pages 524-532

  Pålhagen, Sven ^a,b   Qi, Hongshi ^a   Mårtensson, Björn ^a   Wålinder, Jan ^c   Granérus, Ann Kathrine ^d   Svenningsson, Per ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d LINKÖPING UNIVERSITY   (Sweden)

Author keywords

5 HIAA; BDNF; Biomarker; Cerebrospinal fluid; Citalopram; Corticosterone; HVA; IL 6; Major depression; MHPG; Parkinson's disease; SSRI

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; 5 HYDROXYINDOLEACETIC ACID; ALPRAZOLAM; BRAIN DERIVED NEUROTROPHIC FACTOR; BROMOCRIPTINE; CITALOPRAM; CORTICOSTERONE; DIAZEPAM; ENTACAPONE; HOMOVANILLIC ACID; HYDROXYZINE; HYPNOTIC AGENT; INTERLEUKIN 6; LEVODOPA; OREXIN A; OXAZEPAM; SELEGILINE;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID LEVEL; CHEMICAL ANALYSIS; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DISEASE MARKER; DRUG DOSE INCREASE; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; ANALYSIS OF VARIANCE; BIOGENIC MONOAMINES; BRAIN-DERIVED NEUROTROPHIC FACTOR; CORTICOSTERONE; DEPRESSIVE DISORDER, MAJOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HOMOVANILLIC ACID; HUMANS; HYDROXYINDOLEACETIC ACID; INTERLEUKIN-6; MALE; METHOXYHYDROXYPHENYLGLYCOL; MIDDLE AGED; PARKINSON DISEASE; RADIOIMMUNOASSAY;

EID: 77951259044     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-009-5353-6     Document Type: Article

References (36)

1. AF Leentjens 2004 Depression in Parkinson's disease: conceptual issues and clinical challenges J Geriatr Psychiatry Neurol 17 120 126 10.1177/0891988704267456 15312275 (Pubitemid 39128221)
2. SE Pålhagen M Carlsson E Curman, et al. 2008 Depressive illness in Parkinson's disease-indication of a more advanced and widespread neurodegenerative process? Acta Neurol Scand 117 295 304 10.1111/j.1600-0404. 2007.00986.x 18279483 (Pubitemid 351503335)
3. S Kapur JJ Mann 1992 Role of the dopaminergic system in depression Biol Psychiatry 32 1 17 10.1016/0006-3223(92)90137-O 1:CAS:528:DyaK3sXjs1Ontw%3D%3D 1391289
4. P Willner 1997 The mesolimbic dopamine system as a target for rapid antidepressant action Int Clin Psychopharmacol 12 S7 S14 10.1097/00004850- 199705002-00003 9347387 (Pubitemid 27286565) (Pubitemid 27414585)
5. EJ Nestler WA Carlezon Jr 2006 The mesolimbic dopamine reward circuit in depression Biol Psychiatry 59 1151 1159 10.1016/j.biopsych.2005.09.018 1:CAS:528:DC%2BD28XmtVOitrk%3D 16566899 (Pubitemid 44192421)
6. H Braak E Ghebremedhin U Rüb, et al. 2004 Stages in the development of Parkinson's disease-related pathology Cell Tissue Res 318 121 134 10.1007/s00441-004-0956-9 15338272 (Pubitemid 39362633)
7. R Mayeux Y Stern L Cote JB Williams 1984 Altered serotonin metabolism in depressed patients with Parkinson's disease Neurology 34 642 646 1:STN:280:DyaL2c7mvVCqsA%3D%3D 6200801 (Pubitemid 14143522)
8. SJ Kish J Tong O Hornykiewicz, et al. 2008 Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease Brain 131 120 131 17956909
9. VS Kostić BM Djuricić N Covicković-Sternić, et al. 1987 Depression and Parkinson's disease: possible role of serotonergic mechanisms J Neurol 234 94 96 10.1007/BF00314109 2435855
10. W Kuhn T Müller M Gerlach E Sofic G Fuchs N Heye R Prautsch H Przuntek 1996 Depression in Parkinson's disease: biogenic amines in CSF of "de novo" patients J Neural Transm 103 12 1441 1445 10.1007/BF01271258 1:CAS:528:DyaK2sXhsVOmt7k%3D 9029411 (Pubitemid 27023180)
11. RH Belmaker G Agam 2008 Major depressive disorder N Engl J Med 358 1 55 68 10.1056/NEJMra073096 1:CAS:528:DC%2BD1cXisFWjsQ%3D%3D 18172175
12. T Müller S Muhlack 2007 Acute levodopa intake and associated cortisol decrease in patients with Parkinson disease Clin Neuropharmacol 30 2 101 106 10.1097/01.WNF.0000240954.72186.91 17414942 (Pubitemid 46581203)
13. A Charlett RJ Dobbs AG Purkiss DJ Wright DW Peterson C Weller SM Dobbs 1998 Cortisol is higher in parkinsonism and associated with gait deficit Acta Neurol Scand 97 2 77 85 1:STN:280:DyaK1c7nslSgtw%3D%3D 9517856 (Pubitemid 28085034)
14. CS Wilcox MJ Aminoff JG Millar J Keenan M Kremer 1975 Circulating levels of corticotrophin and cortisol after infusions of L-DOPA, dopamine and noradrenaline, in man Clin Endocrinol (Oxf) 4 2 191 198 10.1111/j.1365-2265. 1975.tb01526.x 1:STN:280:DyaE2M7mslSqsQ%3D%3D
15. J Zhang I Sokal ER Peskind, et al. 2008 CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases Am J Clin Pathol 129 526 529 10.1309/W01Y0B808EMEH12L 1:CAS:528:DC%2BD1cXkvVeitr4%3D 18343778 (Pubitemid 352029270)
16. Z Salehi F Mashayekhi 2009 Brain-derived neurotrophic factor concentrations in the cerebrospinal fluid of patients with Parkinson's disease J Clin Neurosci 16 1 90 93 10.1016/j.jocn.2008.03.010 1:CAS:528: DC%2BD1cXhsVCku7%2FL 19017558
17. X Drouot S Moutereau JP Nguyen, et al. 2003 Low levels of ventricular CSF orexin/hypocretin in advanced PD Neurology 61 540 543 1:CAS:528: DC%2BD3sXmtVemsbY%3D 12939433 (Pubitemid 37025376)
18. K Yasui Y Inoue T Kanbayashi T Nomura M Kusumi K Nakashima 2006 CSF orexin levels of Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration J Neurol Sci 250 1-2 120 123 10.1016/j.jns.2006.08.004 1:CAS:528:DC%2BD28XhtFOhsL%2FI 17005202 (Pubitemid 44665944)
19. AJ Hughes SE Daniel L Kilford AJ Lees 1992 Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases J Neurol Neurosurg Psychiatry 55 3 181 184 10.1136/jnnp.55.3.181 1:STN:280:DyaK383is1Omsg%3D%3D 1564476
20. Spitzer R, Williams J, Gibbon M (1987) Instruction Manual for the Structured Clinical Interview for DSM-III-R. New York State Psychiatric Institute, New York
21. American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders, 3rd edition, revised. American Psychiatric Association, Washington, DC
22. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington, DC
23. K Blennow A Wallin CG Gottfries, et al. 1993 Cerebrospinal fluid monoamine metabolites in 114 healthy individuals 18-88 years of age Eur Neuropsychopharmacol 3 55 61 10.1016/0924-977X(93)90295-W 1:CAS:528: DyaK3sXkt1Squrc%3D 7682460 (Pubitemid 24089493)
24. Pålhagen SE, Wålinder J, Granérus AK (2009) Treatment of major depression in Parkinson's disease improves depressive as well as motor symptoms-indicating a more extensive neurodegenerative process? (Submitted)
25. L Bjerkenstedt G Edman L Flyckt, et al. 1985 Clinical and biochemical effects of citalopram, a selective 5-HT reuptake inhibitor-a dose-response study in depressed patients Psychopharmacology 87 253 259 10.1007/BF00432703 1:CAS:528:DyaL28XivVOjug%3D%3D 3936081 (Pubitemid 16225669)
26. G Nikisch AA Mathé A Czernik, et al. 2004 Stereoselective metabolism of citalopram in plasma and cerebrospinal fluid of depressive patients: relationship with 5-HIAA in CSF and clinical response J Clin Psychopharmacol 24 283 290 10.1097/01.jcp.0000125680.89843.a6 1:CAS:528:DC%2BD2cXlt12it70%3D 15118482 (Pubitemid 38658036)
27. B Mårtensson S Nyberg G Toresson, et al. 1989 Fluoxetine treatment of depression. Clinical effects, drug concentrations and monoamine metabolites and N-terminally extended substance P in cerebrospinal fluid Acta Psychiatr Scand 79 586 596 10.1111/j.1600-0447.1989.tb10307.x 2475012 (Pubitemid 19168605)
28. G Piñeyro P Blier 1999 Autoregulation of serotonin neurons: role in antidepressant drug action Pharmacol Rev 51 533 591 10471417 (Pubitemid 29420214)
29. JF Cryan OF O'Leary SH Jin, et al. 2004 Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors Proc Natl Acad Sci USA 101 8186 8191 10.1073/pnas.0401080101 1:CAS:528:DC%2BD2cXkslCitL8%3D 15148402 (Pubitemid 38698075)
30. RM Post 2007 Role of BDNF in bipolar and unipolar disorder: clinical and theoretical implications J Psychiatr Res 41 979 990 10.1016/j.jpsychires.2006. 09.009 17239400 (Pubitemid 47301944)
31. BS McEwen 2008 Central effects of stress hormones in health and disease: understanding the protective and damaging effects of stress and stress mediators Eur J Pharmacol 583 174 185 10.1016/j.ejphar.2007.11.071 1:CAS:528: DC%2BD1cXjs1Squ74%3D 18282566
32. K Wahlberg PH Ghatan S Modell, et al. 2009 Suppressed neuroendocrine stress response in depressed women on job-stress-related long-term sick leave: a stable marker potentially suggestive of preexisting vulnerability Biol Psychiatry 65 9 742 747 10.1016/j.biopsych.2008.10.035 1:CAS:528: DC%2BD1MXktV2qsbo%3D 19058782
33. JR Seckl JC Campbell CR Edwards, et al. 1990 Diurnal variation of plasma corticosterone in depression Psychoneuroendocrinology 15 485 488 10.1016/0306-4530(90)90071-G 1:CAS:528:DyaK3MXksVOhsrg%3D 1966303
34. KY Ng TN Chase RW Colburn IJ Kopin 1970 l-Dopa-induced release of cerebral monoamines Science 170 953 76 77 10.1126/science.170.3953.76 1:CAS:528:DyaE3cXltFyrs7Y%3D 5452893
35. I Shoulson GA Glaubiger TN Chase 1975 On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients Neurology 25 12 1144 1148 1:STN:280:DyaE28%2Fns1Slsw%3D%3D 812004
36. M Menza RD Dobkin H Marin MH Mark M Gara S Buyske K Bienfait A Dicke 2009 A controlled trial of antidepressants in patients with Parkinson disease and depression Neurology 72 10 886 892 10.1212/01.wnl.0000336340.89821.b3 1:CAS:528:DC%2BD1MXisFeksLs%3D 19092112